Back to first-pass browser

First-pass extracted concept

ICD-based cancer immunotherapy

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

ICD-based cancer immunotherapy uses immunogenic tumor cell death to stimulate antitumor immune responses alongside direct tumor killing.

Source 1DOIPubMed

What problem it solves

It aims to improve cancer treatment by coupling cytotoxicity to adaptive immunity and possible immunological memory.

Source 1DOIPubMed

Evidence Snippets

the development of ICD immunotherapy, which combines the direct cancer killing, antitumor immunity and potential immunological memory has generated significant interests in cancer immunotherapy
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1application promisesupports2023Source 1DOIPubMed

ICD-based cancer immunotherapy combines direct cancer killing, antitumor immunity, and potential immunological memory and is presented as a promising approach for complete cancer elimination and long-term protective immune responses.

Quoted textsource-backed
the development of ICD immunotherapy, which combines the direct cancer killing, antitumor immunity and potential immunological memory has generated significant interests in cancer immunotherapy as a promising approach for achieving complete cancer elimination and long-term protective immune responses
Claim 2delivery challengesupports2023Source 1DOIPubMed

Overcoming biological barriers to deliver ICD inducers or vaccines is an important strategy for improving ICD-based cancer immunotherapy.

Quoted textsource-backed
extensive efforts with great advances have also been made in overcoming biological barriers to deliver ICD inducers or vaccines to improve ICD based cancer immunotherapy
Claim 3scope expansionsupports2023Source 1DOIPubMed

The scope of ICD inducers has expanded beyond conventional chemotherapeutic drugs to include immunoregulatory biomaterials, biomimetic active materials, supramolecular assembled peptides, photodynamic therapy, photothermal therapy, radiation therapy, and electromagnetic energy.

Quoted textsource-backed
Nowadays, the scope of ICD inducers has expanded beyond conventional chemo drugs such as DOX or Carfilzomib, to include immunoregulatory biomaterials, biomimetic active materials, as well as supramolecular assemble peptides and so forth. Apart from chemotherapy, other therapeutic modalities including photodynamic therapy, photothermal therapy, radiation therapy, as well as electromagnetic energy have shown significant potentials in eliciting robust and remarkable ICD antitumor immune response